某药联合化疗对转移性胰腺癌的治疗效果显著
Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy
一项I/II期临床试验显示,daraxonrasib联合化疗在转移性胰腺癌患者中显著缩小肿瘤,深部反应率和无进展生存期显著提高,为晚期胰腺癌治疗带来潜在变革。
该研究显示了深部反应和更长的无进展生存期,可能对晚期胰腺癌的治疗产生重大影响。
Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.
In a presentation of the results from the RMC-GI-102 trial at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the principal investigator said the drug combination not only shrank tumors but also showed encouraging prolonged disease control when used in patients who had not previously received treatment for metastatic disease.
Dr. Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center, New York City, U.S., said, "Pancreatic cancer remains one of the most challenging cancers to treat, particularly because more than half of patients present with disease that has already spread to other organs. We need effective treatments that can achieve deep responses and prolong disease control to curb this aggressively devastating disease.
"For most patients with previously untreated metastatic pancreatic cancer, chemotherapy remains the foundation of treatment. Although chemotherapy can shrink tumors by a modest amount and help some patients, the cancer frequently develops resistance and begins growing again."
Most patients with metastatic pancreatic cancer treated with standard chemotherapy survive for between eight and 11 months, and only 3% are alive five years after diagnosis. Tumor shrinkage is seen in only 23%–42% of patients treated with chemotherapy, and most tumors start to grow again after five to six months.
Deeper responses and longer disease control
"What is particularly encouraging about these new and updated results I am presenting today is that we are beginning to see not only a higher percentage of tumor response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," he said.
As of Sept. 28, 2026, 61 patients had received the drug combination. The median (midpoint) follow-up was 18.3 months, with a range of 13.1 to 23.7 months. Tumors shrank or disappeared in 60.7% of patients (the objective response rate). This included complete responses in 8.2% of patients in whom tumors were no longer detectable, and tumors stopped growing in 90.2% of patients (the disease control rate). The median time before tumors returned or started growing again was 12.8 months (the median progression-free survival).
"This represents a potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer, already outpacing the high end for the historical overall survival of 8.5–11.1 months with conventional chemotherapy," said Park.
Targeting the RAS growth signal
More than 90% of pancreatic cancers have a mutation in the RAS gene that drives the cancer's growth. RAS acts like a molecular switch that tells cells when to grow. In pancreatic cancer, the switch becomes stuck in the 'on' state, continuously sending signals that drive cancer cells to divide and grow. This makes the RAS mutation a critical target for new treatments but, until recently, targeting RAS successfully was not possible.
Daraxonrasib is designed to stop an active protein called RAS (ON) and interfere with the signals that pancreatic cancer cells depend on for survival. RMC-GI-102 is a study that combines daraxonrasib with standard chemotherapy as a first-line treatment to test this hypothesis.
Patients in the trial received 200 mg of daraxonrasib, taken orally once a day, and two chemotherapy drugs, gemcitabine and nab-paclitaxel, given by intravenous injection on days 1 and 15 of each treatment cycle. Gemcitabine was given at 1,000 milligrams per square meter of body surface area (1,000 mg/m²) and nab-paclitaxel at 125 mg/m².
"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumor responses in a substantial proportion of patients, together with durable disease control, with a median progression-free survival exceeding one year," said Park.
The most common adverse side effects included rash, diarrhea, fatigue and those known to be associated with chemotherapy such as cytopenia (a reduction in some blood cells), which were managed adequately with standard medical interventions. Discontinuation of treatment due to daraxonrasib-related side effects was infrequent, occurring in 5% of patients.
Larger trial to test survival benefit
Park said, "These more mature results are particularly exciting because we are now seeing not only substantial tumor shrinkages, including complete responses, but also durable disease control, with median progression-free survival exceeding one year, nearly doubling that reported historically with standard chemotherapy. Importantly, the 12-month overall survival rate of 76.6% provides further insight into the sustained clinical benefit. Together, these findings represent a potentially transformative advance in our pursuit of more effective first-line treatments for metastatic pancreatic cancer.
"However, this is an early-phase study, and the results must be interpreted carefully because patients were not compared with patients receiving chemotherapy alone. The next step is to determine whether these remarkable early findings translate into improved outcomes in a large randomized clinical trial. This is precisely the question being addressed by the global phase 3 RASolute-303 trial, which is evaluating daraxonrasib both as a standalone treatment and in combination with gemcitabine and nab-paclitaxel, compared with chemotherapy alone."
Park is the principal investigator of RASolute-303. "The results from RMC-GI-102 provide important clinical evidence supporting the treatment strategy now being evaluated in the RASolute-303 study," he said.
Elena Garralda, chair of the EORTC-NCI-AACR Symposium (ENA) and co-director of the Vall d'Hebron Institute of Oncology's clinical research program, was not involved with the study.
She commented, "Pancreatic cancer is one of the most difficult cancers to treat successfully, particularly if it has started to spread to other parts of the body. These results are exciting because they show the combined treatment could potentially significantly improve patients' overall survival, as well as the time before tumors start to grow again.
"This study is one of several being presented at ENA today that demonstrate that it is now possible to target the RAS mutations driving cancer growth. Importantly, it shows that RAS-targeted therapies can be combined with existing treatments to achieve potentially more durable clinical benefits for patients, and that it can be given to patients immediately as first-line therapy, enabling the treatment to start at an earlier stage in the course of advanced disease."
RAS mutations drive other cancers too, including certain lung, bowel, biliary tract, appendiceal and gynecological cancers. Clinical trials for each of these diseases would be needed to see if the combination of daraxonrasib and chemotherapy could improve patient outcomes.
More information
Daraxonrasib plus Gemcitabine/Nab-Paclitaxel (GnP) as First-Line (1L) Treatment for Patients (Pts) with Metastatic Pancreatic Adenocarcinoma (mPDAC), 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 18–20 November 2026.
Provided by European Organisation for Research and Treatment of Cancer
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy (2026, November 20) retrieved 20 November 2026 from https://medicalxpress.com/news/2026-11-metastatic-pancreatic-cancer-treatment-combination.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com